logo-loader
viewOpen Orphan Plc

Open Orphan PLC targeting 'value creation and rapid scale-up'

Proactive Research analyst Emma Ulker discusses the opportunity with Open Orphan PLC (LON:ORPH).

She says the firm's targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market - a space which is growing at around 11% a year.

Ulker adds they're looking to combine a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies.

Quick facts: Open Orphan Plc

Price: 6.57 GBX

AIM:ORPH
Market: AIM
Market Cap: £16.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan Plc named herein, including the promotion by the Company of Open Orphan Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan partnership with Ipsen Group 'already delivering substantial...

Open Orphan Plc's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing plans to make its Venn Life Sciences business profitable by way of a three-year preferred partnership agreement with French pharma company Ipsen Group. Friel says the deal is the first of many...

6 days, 4 hours ago

2 min read